Bah Humbug Vitamin D (12.20.2024)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Read Article
95 IBD pts had Magnetic resonance enterography (MRE). While 6/95 (6.3%) developed IBD-arthritis (mean 11 mos), finding Sacroiliitison MRE did not increase this risk. IBD arthritis risk was linked to arthralgia (OR 84) & extraintestinal manifestations (OR 7.4)… https://t.co/NGWGKn75jG https://t.co/IqY6XHWqqy
Dr. John Cush @RheumNow( View Tweet )
Rheumatic findings in sarcoidosis are found in 10–40% of pts and include bone lesions, acute arthritis, chronic arthritis, axial disease, dactylitis, and sarcoid myopathy, https://t.co/WsfmKUS2n5 https://t.co/3j8OHgw7AS
Dr. John Cush @RheumNow( View Tweet )
Abuse of the Safety-Net 340B Drug Programs
Dr. Madelaine Feldman has written an important commentary on the 340B Drug Pricing Program, a safety-net program that would allow vulnerable populations to receive expensive new therapies. But she points out that "this well-intentioned program has strayed from its original purpose", allowing
Read Article
Biosimilars Do Impact Biologic Drug Costs
MedPage Today
Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic drop in net spending for these products -- even though biosimilars barely dented Humira prescription rates.
Read Article
International Map of Axial SpA study surveyed 5557 axSpA pts (3231 Europe, 770 USA); mean 44 yrs old; 55% females. mean BASDAI was 5.4 (75% had active disease -BASDAI ≥4). Active Dz highest in S. Africa 87%, vs 68% in Asia. Active Dz assoc w/ active functional limitation,… https://t.co/j8CjuLHHjD https://t.co/tV9S3b7YCM
Dr. John Cush @RheumNow( View Tweet )
JAMA FULL READ review and overview of Axial Spondyloarthritis by Drs. Deodhar & Bittar
- Dx often delayed 6-8 yrs
- Sensitivity/Specificity of: HLA-B27 (50%/90%), CRP (35%/91%), Xray sacroiliitis (66%/68%) or MRI (78%/88%). Great tables, figs, Xrays &Reference!… https://t.co/UbqVOr2iDx https://t.co/Ye5mYcbYX2
Dr. John Cush @RheumNow( View Tweet )
Don’t Buy Guitars (12.6.2024)
This year at ACR24, the RheumNow faculty and reporters were prolific, generating >800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days! You can best review and learn ACR24 by A) Rheumatology Roundup; b) Topic Panel videos; and c) Topic podcasts.
Read Article
Infertility linked to post-childbrith onset of systemic autoimmune disease
EurekAlert!
Women who experience infertility but do not use fertility treatments have a higher risk of developing a group of conditions called systemic autoimmune rheumatic diseases (SARD) in the nine years after a naturally conceived birth compared to women without fertility problems.
Read Article
ICYMI: Reproductive Issues in axSpA: Fertility and Pregnancy
Axial spondyloarthritis (axSpA) affects young patients with symptom onset occurring in early adulthood. Apart from pain and quality of life, reproductive issues also arise because patients who are diagnosed with the disease are also in their reproductive age. Two interesting abstracts about
Read Article
ACR24 SpA Panel: Key Discussions on Spondyloarthritis
Join panelists Dr. Sheila Reyes, Dr. Adela Castro, Dr. Lihi Eder and Dr. Marina Magrey as they discuss key highlights and takeaways on spondyloarthritis sessions and abstracts presented at the 2024 ACR meeting in Washington,… https://t.co/XGcR6WDBFO https://t.co/0mJ08nheJJ
Dr. John Cush @RheumNow( View Tweet )
ACR24: Rheumatology Roundup
Join Drs. Jack Cush and Artie Kavanaugh as they review 15+ presentations and abstracts from the 2024 ACR Convergence meeting in Washington, DC.
Read Article
Assessment of axSpA
Dr. Antoni Chan reviews abstracts 0818 and 0819, presented at #ACR24.
https://t.co/2qI6DnnflP https://t.co/BuTdnlMfxq
Dr. John Cush @RheumNow( View Tweet )
Predicting flares in rheumatic diseases with machine learning
Rheumatic diseases, such as axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA), are marked by unpredictable disease flares that adversely impact quality of life and long-term outcomes.… https://t.co/6oFRp0zyBw https://t.co/fcMrJOg4mM
Dr. John Cush @RheumNow( View Tweet )
How New Medications are Reframing Imaging Abnormalities in axSpA
Bimekizumab (BKZ), a monoclonal antibody targeting IL-17A and IL-17F, was evaluated in the BE MOBILE 1 and 2 trials for non-radiographic and radiographic axSpA, respectively. It showed significant clinical… https://t.co/wJYh5XCVfw https://t.co/qZ2MnGVXXG
Dr. John Cush @RheumNow( View Tweet )
Assessing ASAS Criteria: CLASSIC Study Results
Dr. Adela Castro discusses abstract 0820, presented at #ACR24
https://t.co/rlzL8nAsiI https://t.co/7lbXWE3gdJ
Dr. John Cush @RheumNow( View Tweet )
Cycling vs Switching after TNFi Failure in axSpA
Dr. Lihi Eder discusses abstract 0603, presented at #ACR24
https://t.co/qkDuutgqvv https://t.co/Agqopk6bh2
Dr. John Cush @RheumNow( View Tweet )
NEW ONLINE POSTER: Safety of a JAKi presented at EULAR 2024!
View safety across 15,000 patient-years of data from 11 Phase 3 trials, including adult patients with RA, PsA, AS, and nr-axSpA. This poster is sponsored by AbbVie US Medical Affairs.
https://t.co/gIFWRqOGmD https://t.co/L0YttKihdf
Dr. John Cush @RheumNow( View Tweet )
Gender Differences in SpA
#ACR24 provided its attendees with vast information about disease pathophysiology, diagnosis and treatment covering both clinical and basic sciences. One of the hot topics during the meeting was gender differences in SpA. Three abstracts presented… https://t.co/iEh0s3sIhc https://t.co/SRhz0Uwwwv
Dr. John Cush @RheumNow( View Tweet )
Highlights in axSpA
Dr. Marina Magrey discusses highlights in axSpA from the first day at #ACR24
https://t.co/LvvmzlXWw7 https://t.co/thf9MiMo32
Dr. John Cush @RheumNow( View Tweet )
RheumNow Day 2 Recap: #ACR24 Highlights
Catch the latest insights from the ACR Annual Meeting, where leading experts share groundbreaking research and clinical advances in rheumatology. Don’t miss our live coverage of key takeaways and trends shaping the future of patient care.… https://t.co/F3rZzOTiSJ https://t.co/t3wROMBe7D
Dr. John Cush @RheumNow( View Tweet )
Predicting flares in rheumatic diseases with machine learning
Rheumatic diseases, such as axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA), are marked by unpredictable disease flares that adversely impact quality of life and long-term outcomes. Advances in machine learning (ML) provide a promising avenue for predicting these
Read Article
How New Medications are Reframing Imaging Abnormalities in axSpA
Bimekizumab (BKZ), a monoclonal antibody that selectively targets both IL-17A and IL-17F, was evaluated in the BE MOBILE 1 (non-radiographic axSpA) and BE MOBILE 2 (radiographic axSpA) trials and found to yield significant
Read Article
RheumNow Day 4 Recap: ACR Convergence 2024 Highlights https://t.co/WvQB7y0bkm
Links:
Dr. John Cush @RheumNow( View Tweet )
axSpA: Moving the needle in time to diagnosis
The journey to axial spondyloarthritis (axSpA) diagnosis is often prolonged and challenging. Understanding the factors contributing to the delays is important to improve the clinical, psychological, social and economic outcomes.… https://t.co/wnwtj8jj0q https://t.co/Pds2uxVfJV
Dr. John Cush @RheumNow( View Tweet )
Recent Blogs
With their publication in June 2022 (1), the 3rd iteration of the Group for Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Treatment recommendations for Psoriatic Arthritis (PsA) may have set a record or sorts.
Read Post
